ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs
ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
Inclusion Criteria:
Exclusion Criteria:
Nigatake, Niigata 951-8520, Japan
Kita-Adachi County, Saitama 362-0806, Japan
Suntou County, Shizuoka 411-8777, Japan
Bunkyo-ku, Tokyo 113-0021, Japan
Chuo-ku, Tokyo 104-0045, Japan
Chuo-ku, Tokyo 104-8560, Japan
Koto-ku, Tokyo 135-8550, Japan
Meguro-ku, Tokyo 152-8902, Japan
Minato-ku, Tokyo 105-8470, Japan
Shinagawa-ku, Tokyo 142-8666, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Hwasun-Gun, 58128, South Korea